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Abstract
Introduction Women who choose to conceive a baby with
a partner living with HIV or a partner whose HIV serostatus
is unknown in HIV-endemic settings need prevention
strategies to mitigate HIV acquisition during conception
and pregnancy.
Methods and analysis We are conducting a singlearm longitudinal study offering oral tenofovirdisoproxil
fumarate/emtricitabine (TDF/FTC) as pre-exposure
prophylaxis (PrEP) for periconception use to 350 HIVuninfected women in KwaZulu-Natal, South Africa. PrEP
is offered as part of woman-centred safer conception
programme that promotes couples-based HIV counselling
and testing, antiretroviral therapy for partners who
are HIV-infected, treatment for sexually transmitted
infections and safer conception strategies, such as limiting
condomless sex to peak fertility. We enrol HIV-uninfected
women who are not currently pregnant, in a stable
relationship (≥6 months) with a partner living with HIV
or of unknown serostatus, and personal or partner plans
for pregnancy in the next 12 months. We follow enrolled
women for 12 months. Women who become pregnant
are followed through pregnancy outcome, independent of
their decisions regarding PrEP use. The primary objective
of the study is to evaluate the uptake of and adherence
to PrEP during the periconception period and pregnancy.
Secondary outcomes include the uptake of other safer
conception strategies. We also measure clinical outcomes
including HIV seroconversion rates and pregnancy and
infant outcomes. Finally, we will explore conduct and
evaluate qualitative interviews in 25 participants to further
inform our conceptual framework for periconception PrEP
uptake and adherence among HIV-exposed women in
South Africa.
Ethics and dissemination The protocol has been
approved by the Human Research Ethics Committee at
the University of the Witwatersrand (Johannesburg, South
Africa) and the Institutional Review Board of Partners
Healthcare (Boston, Massachusetts, USA). Study findings
will be made available to interested participants. Results
will be presented to local health officials and stakeholders
at meetings. Investigators will share the results at
meetings and in manuscripts. De-identified quantitative
data will be made available.

Strengths and limitations of this study
►► This study will objectively measure uptake of and

adherence to pre-exposure prophylaxis (PrEP)
during conception and pregnancy.
►► This study will evaluate the use of PrEP during pregnancy in South Africa where tenofovir disoproxil fumarate/emtricitabine is currently contraindicated in
pregnancy.
►► Enrolling women who may be exposed to HIV during
conception attempts, but without requiring PrEP use,
allows for evaluation of uptake.
►► Enrolling women independent of their partners allows for evaluation of adherence outside of mutually disclosed HIV-serodifferent partnerships.
►► We will not test male partners’ HIV-serostatus or
necessarily hear their perspective directly as men
are not enrolled.

Trial registration number The protocol is registered
with the South African Health Products Regulatory
Agency (SAHPRA, formerly known as the Medicine
Controls Council, MCC#20170131) and ClinicalTrials.gov
(NCT03194308); Pre-results.

Introduction
In HIV-endemic settings, many HIV-uninfected women choose to conceive a baby
with a partner living with HIV or whose
serostatus is not known.1–4 For a woman who
cannot depend on a partner to test, initiate
and adhere to ART, and suppress HIV RNA,
condomless sex puts her at risk of acquiring
HIV and increases the risk of perinatal
transmission to her child.5 In South Africa,
HIV incidence has declined since 2012, but
women of reproductive age have the highest
incidence at 0.93%.6 Even with the roll-out
of test and treat antiretroviral therapy (ART)
policies in South Africa, in some settings,
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HIV incidence among women continues to rise even as
incidence declines among men,7 reflecting ongoing challenges to supporting men living with HIV to engage and
remain in care.8–12
Preventing HIV infection among women of reproductive age is the first pillar of reducing perinatal transmission.13 Although pregnant women living with HIV are a
major focus of services to prevent perinatal transmission,
HIV prevention prior to pregnancy receives relatively
little attention. The contribution of intended conception
to incident HIV infection is important in many HIV-endemic settings given the importance of having children, a
lack of programmes addressing periconception transmission and high HIV prevalence.14
Daily, oral tenofovir disoproxil fumarate/emtricitabine
(TDF/FTC) for pre-exposure prophylaxis (PrEP) dramatically reduces a woman’s risk of HIV acquisition and may
be an important female-controlled option for reducing
the risk of periconception HIV acquisition.15 16 Evidence
suggests it is safe to use during pregnancy.17 Understanding whether daily, oral PrEP is feasible for uninfected women seeking pregnancy is critical to reducing
HIV incidence among women and their children.
Placebo-controlled trials identified adherence as a
major challenge to long-term PrEP use among women.18
However, women are eager for prevention strategies that
allow for conception,19–21 and we hypothesise that adherence to a proven prevention strategy, for a limited time
with the motivation to have a healthy child, will confer
the drug levels required to prevent HIV transmission.
Supporting our hypothesis is the finding that women had
a high adherence prior to conception in clinical trials and
demonstration projects of PrEP.19 22–24
Our conceptual framework is based on an ecological
framework published by van der Straten et al and adapted
based on our periconception risk behaviour conceptual
framework.25–27 This framework assumes that uninfected
women who want to have a child with an infected or
unknown serostatus partner will experience individual,
couple and community-level factors that influence PrEP
initiation and adherence behaviour. At the individual
level, she may have excellent knowledge of safer conception strategies, be optimistic about PrEP efficacy and
perceive herself to be at high risk for acquiring HIV.
However, on the dyadic level, she and her partner may
not communicate or trust one another, making it hard for
her to adhere to daily medication. If she feels that childlessness and/or being HIV-infected is highly stigmatised
in the community, then she may be more motivated to
participate in periconception PrEP. Our mixed methods
data will allow us to develop this framework to inform
interventions for women seeking HIV-prevention during
periconception and pregnancy.
This manuscript describes the ZINK protocol. ‘Zivikele
ngaphambi kokukhulelwa’ means, ‘Protecting yourself before
pregnancy’ in isiZulu. This project will inform whether
daily, oral PrEP is a feasible component of comprehensive HIV prevention for South African women who intend
2

to conceive a baby and may be exposed to HIV. Given
the repercussions of acquiring HIV during conception
and pregnancy, periconception PrEP is an important step
towards supporting women to safely meet reproductive
goals.

Methods and analysis
Study design
The Zivikele ngaphambi kokukhulelwa (ZINK) or Protecting
yourself before pregnancy study is a single-arm longitudinal
study offering safer conception counselling to HIV-exposed women in Durban, South Africa. The safer conception package emphasises the importance of couples-based
HIV counselling and testing (CHCT), ART for the
infected partner, treatment for sexually transmitted
infections (STIs), and safer conception strategies, such
as limiting sex without condoms to peak fertility. We also
offer TDF/FTC as PrEP. Study participants are followed
for a period of 12 months. Those with pregnancy during
the 12-month follow-up are counselled about HIV risk-reduction during pregnancy, offered PrEP and followed
through to pregnancy outcome (regardless of PrEP use).
Population
ZINK participants are women aged 18–35 years who are
HIV-negative with personal or partner plans for pregnancy with an infected or unknown serostatus partner.
Women are recruited in Durban, KwaZulu-Natal, South
Africa where nearly 40% of women who attend antenatal clinics test positive for HIV infection.28 PrEP is
currently contraindicated for use by pregnant women
in South Africa, due to local concerns regarding safety
outlined by the South African Health Products Regulatory Agency (SAHPRA, formerly known as the MCC).29
Due to challenges recruiting HIV-serodifferent couples in
this setting, we recruit women as individuals30; however,
women are invited to bring their partners to the study site
for counselling and information.
Recruitment for this study is through fieldwork teams
reaching out directly to women at local Department of
Health primary healthcare clinics within the eThekwini
District, gathering spots near the research site (such as
hair salons and service queues), and through word-ofmouth promotion from enrolled participants and others
who know of the study. We are also planning community
events in consultation with our affiliate Community Advisory Board (CAB). Recruitment began in November 2017
and is expected to last 30 months.
Study aims and outcomes
The primary aims of the study are to: (1) determine PrEP
uptake and adherence among all enrolled participants
(by self-report, electronic monitoring, plasma and blood
samples), (2) determine PrEP adherence among women
who take PrEP during the periconception period and
pregnancy and (3) explore adherence facilitators and
barriers during periconception and pregnancy to further
Matthews LT, et al. BMJ Open 2019;9:e027227. doi:10.1136/bmjopen-2018-027227
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inform our conceptual framework for periconception
PrEP uptake and adherence.27 Additional outcomes of
interest include uptake of safer conception strategies
including CHCT, ART for the infected partner and contraception uptake for those who decide not to conceive after
careful consideration. We also measure clinical outcomes
including HIV seroconversion rates, pregnancy outcomes
(eg, miscarriage, stillbirth and live birth) and infant
outcomes (eg, weight, length and observed congenital
anomalies).
Eligibility criteria
Study inclusion and exclusion criteria are presented in
box 1 and include (via self-report) being woman; between
ages 18 and 35 years; reporting an HIV-seropositive or
unknown HIV serostatus partner; not on long-acting
contraception (IUD (Intrauterine Device), injectable or
implanted contraception); and personal or partner plans
to have a child within the next year. Interested women
are screened for infertility by history31 and participants
who fail to meet the fertility criteria are considered ineligible. Women who are eligible based on the self-report
data complete biological screening. They are eligible to
enrol in the study if they test negative for pregnancy and
HIV and are not co-enrolled (checked via fingerprint32)
in other research studies that may conflict with our procedures (eg, vaccine trials, PrEP projects and so on).
Informed consent procedures
Interested women are asked to complete a brief verbal
informed consent prior to completing the screening questions (box 1). Women are eligible after completing the
screening questions will be invited to complete an initial
written informed consent where the secondary, biological
screening process will be explained (box 1). If women
are eligible for study enrolment, they will be invited to
complete an in-depth informed consent process for study
enrolment and participation.
The Research Assistants will use informed consent documents available in both English and isiZulu as a guide to
discuss all the content in the informed consent with the
potential participant. The consent forms will be reviewed
orally by a study representative and the participant will
be encouraged to ask detailed questions. Women who
meet study inclusion/exclusion criteria and complete the
informed consent process and give signed consent will
then be enrolled.
Study activities
Study activities and corresponding visit schedules are
shown in table 1 and further explained below.
Counselling
At the enrolment visit, women are offered a package of
safer conception counselling based on South African
guidelines.33 These guidelines recommend that HIV-uninfected women who want to conceive a child with a partner
living with HIV should encourage partner testing and
serostatus disclosure within the partnership, encourage
Matthews LT, et al. BMJ Open 2019;9:e027227. doi:10.1136/bmjopen-2018-027227

partner to initiate ART, delay sex without condoms until he
achieves HIV RNA suppression or is on ART for 6 months,
consider contraception to delay pregnancy until safer
conception strategies implemented, limit condomless sex
to peak fertility, and/or consider sperm washing, donor
sperm and adoption as alternatives. In this study, safer
conception counselling occurs at baseline and at each
visit thereafter for non-pregnant women. Comprehensive
counselling is performed by trained study counsellors in a
group format, with the option of one-on-one counselling
sessions based on participant preference and feasibility
of convening a group. We developed and pilot tested
locally relevant tools and visual graphics to communicate
key concepts in prior studies34 35 (see figure 1A-C for key
concepts).
Women who initiate PrEP participate in brief adherence counselling and support sessions at each visit to
discuss barriers to and promoters of adherence. A group
format is pursued given interventions that target social
networks and strengthen group ties have been used to
empower marginalised groups and to effect health-related behaviour change related to HIV prevention.36–38
Box 1

Inclusion and exclusion criteria

Verbal screening inclusion criteria
►► Female.
►► Aged between 18 and 35 years.
►► Sexually active.
►► Likely to be fertile based on responses to reproductive history

assessment.
►► Personal or partner desire to have a child in the next year.
►► With a stable (together for at least 6 months) partner, she reports

as HIV-infected or HIV-serostatus unknown (if >1 desired pregnancy
partner, we will ask her to identify the most likely pregnancy partner
based on her own assessment of sexual frequency, fertility and so
on).
►► Able to participate in the informed consent process.
►► Fluent in English or isiZulu.

Secondary inclusion after informed consent
►► Co‐enrolment in studies which may conflict with participation in this

study.
►► HIV-negative (rapid testing).
►► Not pregnant (by urine beta-hCG testing).

Exclusion criteria
►► HIV positive.
►► Pregnant.
►► No desire to have a child in the next 12 months.
►► Living at or planning to relocate to a location incompatible with

study participation in the next year.
►► Active drug or alcohol use that, in the opinion of the research study

team, would interfere with adherence to study requirements.
►► Active illness requiring systemic treatment and/or hospitalisation

within 30 days prior to study entry that in the opinion of the research
study team, might otherwise interfere with adherence to study
requirements.
►► Inability to adhere to the study schedule and/or study procedures.
beta-hCG, beta-human chorionic gonadotropin.
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Table 1 Study procedures for non-pregnant and pregnant participants
Procedures

Enrolment

M1

M3

M6

M9

M12

Counselling
 Safer conception counselling
 Adherence support if taking PrEP
Laboratory
 Urine pregnancy test*
 HIV rapid test
 STI symptom screen
 HBV serology if initiating PrEP
 Creatinine if initiating PrEP and quarterly while on PrEP
 Blood sample for tenofovir levels if on PrEP
Sociobehavioural data
 Sociodemographic information
 Brief questionnaire
 Full questionnaire
 Weekly SMS sexual behaviour data
 MEMS cap adherence data and questionnaire if on PrEP
 In-depth interviews with a subset of women
*Once pregnancy is diagnosed, women reconsent to participate in the study and are seen monthly for HIV testing and safety monitoring.
They maintain a schedule for quarterly counselling and adherence support. A postpregnancy follow-up visit will assess pregnancy and infant
outcomes.
HBV, hepatitis B virus; MEMS, Medication Event Monitoring System; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.

Participants will also have the option of participating in
one-on-one counselling sessions based on their preference and schedule.

Figure 1 Locally-relevant images developed to convey
key safer conception strategies in the safer conception
counselling sessions. (A) Treatment as prevention. (Top panel)
The man is not taking ART, has a high viral load and there is
a high risk of transmitting to his partner. (Down panel) The
man is taking ART, has a suppressed viral load and the risk
of transmitting to his partner is minimized. (B) PrEP. The man
is not taking ART, has a high viral load and there is a high risk
of transmitting to his partner. In (B), the woman is taking PrEP
which protects her from acquiring HIV. (C) Timing condomless
sex to peak fertility. In this image, the couple is evaluating
a calendar to time condomless sex to peak fertility. ART,
antiretroviral therapy; PrEP, pre-exposure prophylaxis.

Laboratory
Participants complete beta-HCG urine pregnancy testing,
individual HIV counselling and testing (HCT), and
syndromic screening for STIs at each study visit. Study
staff will follow-up with participants who seroconvert to
promote linkage to care and conduct genotyping. Participants with a positive pregnancy test are referred to antenatal care and those with STI symptoms are referred to a
local clinic for treatment.
Women who choose to initiate PrEP undergo blood
testing for renal function (creatinine) and for hepatitis B
infection. Women with abnormal renal function (serum
creatinine >89 µmol/L and estimated glomerular filtration rate (eGFR) <60 mL/min or serum creatinine >85
µmol/L for pregnant women) or active hepatitis B infection (hepatitis B surface antigen positive) are instructed
to stop PrEP.
Renal function testing is repeated quarterly in accordance with CDC and WHO guidelines for safety monitoring. PrEP can be stopped at any point should there be
the abnormal renal function as per the above definition.
PrEP can be re-started if serum creatinine and/or eGFR
levels return to normal. Pregnant women who decide to
continue PrEP during pregnancy are retested for hepatitis
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Table 2 Weekly SMS sexual behaviour survey delivered to
their mobile phone in their language of choice (English or
isiZulu)
Question

Response options

Did you have sex in
the past 7 days?

1.
2.
3.
1.
2.
3.
4.

Yes
No → stop questionnaire
I prefer not to answer
Healthy baby partner
Other partner(s)
Healthy baby and other partners
I prefer not to answer

1.
2.
3.
4.
1.
2.
3.
4.

Every time
Some of the time
Never
I prefer not to answer
Yes
No
Do not know
I prefer not to answer

Which partner(s)?

I used a condom…

Were you in your
fertile period?

B and kidney function at the time of their positive pregnancy test. All women who chose PrEP during pregnancy
undergo renal function testing every 3 months until pregnancy outcome.
Questionnaires
At month 0, 6 and 12, a full questionnaire is administered
to assess constructs within our conceptual framework for
periconception risk behaviour (eg, risk perception, reproductive autonomy and HIV stigma)27 (online supplementary appendix 1). Constructs are measured using
instruments validated in this setting. Questionnaires are
administered via face-to-face interviews with a trained
research assistant fluent in English and isiZulu, which is
the dominant local language. At month 3 and 9, a brief
questionnaire is administered to explore safer conception
behaviours including self-reported partner HIV status,
delay of sex without condoms until the partner on ART is
virologically suppressed, and access to additional services
such as sperm washing.
At the enrolment visit, participants are asked to sign
up for a weekly four-question SMS sexual behaviour
survey delivered to their mobile phone. The questions
and response options are listed in table 2. These password-protected SMS-reported sexual behaviour data will
allow for the measurement of adherence relative to HIV
exposure.39

Women are counselled to continue PrEP for at least 28
days after the last HIV exposure.
PrEP uptake is defined as the proportion of enrolled
women who collect at least 1 month’s supply of PrEP
within the first 12 months of study participation. Women
may choose to initiate/discontinue PrEP at any time
during the periconception period. At each quarterly visit,
a 90-day prescription is given to participants (non-pregnant and pregnant) who chose to use PrEP. Women who
become pregnant may choose to continue or initiate PrEP,
with a plan to continue through to pregnancy outcome or
until her risk is resolved.
Participants taking PrEP are provided AARDEX Medication Event Monitoring System (MEMS), a bottle cap
with an electronic chip that clocks bottle openings. At
each study visit, MEMS data will be downloaded by study
staff and a questionnaire will be completed to evaluate for
self-reported adherence. We will evaluate adherence to
PrEP through plasma tenofovir (TFV) and diphosphorylated tenofovir (TFV-DP) levels in dried blood spots.
Samples will be collected 3 months after PrEP initiation
and at quarterly visits thereafter. Detectable (>0.31 ng/
mL) TFV indicates at least one dose in the prior 7
days, >10 ng/mL indicates dosing in the last 2–3 days
and >40 ng/mL indicates dosing in the last 24 hours and
is associated with HIV protective efficacy.42 43 We anticipate performing the DBS TNF-DP assay on 20 percent of
the total number of samples. The TNF-DP data will give a
sense of longer-term adherence and may help assess the
‘white coat’ effect in this sample.44–46 Adherence questions at each visit and sexual behaviour data will be used
to evaluate for adherence relative to HIV exposure or
‘prevention-effective’ adherence.18

PrEP use
Participants who choose to use PrEP are offered oral,
daily TDF/FTC PrEP (provided by Gilead) according to
US CDC guidelines for periconception PrEP and WHO
Guidelines for PrEP use among those at substantial risk
for acquiring HIV.40 41 Women are counselled to use PrEP
for 7 days (as per WHO 2016 guidance) before engaging
in sex without condoms or other backup protection.

In-depth qualitative individual interviews
In-depth qualitative individual interviews will be
conducted with a subset of up to 25 women based on a
‘purposeful sampling’ framework.47 Trained research
assistants will conduct initial (up to 6 months after enrolment) and exit qualitative interviews to explore factors
affecting PrEP uptake and adherence during periconception and pregnancy. Pregnant and non-pregnant women
will be selected from three groups of roughly equal distribution including (1) those who did not choose PrEP
as part of a safer conception strategy, (2) those who
chose PrEP and/or have detectable plasma TFV and/
or >80% MEMS adherence and (3) those who chose PrEP
but have undetectable plasma TFV and/or <80% MEMS
adherence. Additionally, we will follow women over the
course of the study and offer repeat event-triggered qualitative interviews after major life events such as pregnancy,
major change in partnership (eg, participation in CHCT,
disclosure and separation from current partner) or
change in PrEP use. Based on our conceptual framework,
we assume that uninfected women who want to have a
child with an infected or unknown serostatus partner
will experience individual, couple and community-level
factors that influence PrEP initiation and adherence
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behaviour. At the individual level, she may have excellent
knowledge of safer conception strategies, be optimistic
about PrEP efficacy and perceive herself to be at high risk
for acquiring HIV. However, on the dyadic level, she and
her partner may not communicate or trust one another,
making it hard for her to adhere to daily medication. If
she feels that childlessness and/or being HIV-infected is
highly stigmatised in the community, she may be more
motivated to participate in periconception PrEP (online
supplementary appendix 2.) By collecting qualitative data
as well as quantitative covariates that reflect the constructs
of this framework, our mixed methods data will allow us
to adapt this framework as appropriate to inform interventions for women seeking HIV prevention during periconception and pregnancy.

Women will be reimbursed 250 South African Rand
(~20 US$) per scheduled visit consistent with South Africa’s local guidance.
Patient and public involvement
Years of mixed methods research with men and women
affected by HIV informed this proposal.114 19 28 47 48 In
addition, the study team consulted with MatCH Research
Unit’s affiliate CAB who informed our understanding
and appreciation of community members’ personal
and familial experiences related to a woman’s choice to
have a child with a partner who is living with HIV or with
an unknown serostatus partner. They also aided in our
understanding of women’s need for, and the complexities
related to, informed and supported prevention strategies
to reduce periconception HIV acquisition risk. The CAB
advised the research team on appropriate recruitment
venues, recommended that study team members present
the study at community council meetings, and posted
study flyers at clinics and community gathering spots.
In addition to recruitment efforts by the study team
and the CAB, the participants themselves are involved in
ongoing word-of-mouth recruitment. The results of the
study will be disseminated to participants at community
gatherings organised by the study team in conjunction
with CAB members.

Pregnant participants
Participants who become pregnant during the study
have the option to continue participating in the study
(per GCP guidelines a woman who becomes pregnant
must reconsent to participate in this study). If a woman
has not chosen PrEP, then she can choose to start. If she
has already chosen PrEP, then she can choose whether
or not to continue. Pregnant participants are referred
to their local clinic for antenatal follow-up and care.
Pregnant participants receive counselling regarding
the risks and benefits of using PrEP during pregnancy.
Women who plan to reduce HIV exposure without PrEP
(eg, partner on ART with suppressed viral load, routine
condom use and HIV-negative partner) will be encouraged to pursue these methods of risk reduction. Women
who cannot confidently implement strategies to reduce
HIV acquisition risk will be supported to start or to
continue to use PrEP, during pregnancy. This approach
is consistent with US CDC and WHO guidelines for
PrEP use,40 41 but is not part of South African guidelines
where TDF/FTC as PrEP is contraindicated for use in
pregnancy given safety concerns.29 At the conclusion of
pregnancy, women will be asked about the pregnancy
outcome and their clinical charts will be reviewed to
collect additional relevant data, such as live birth, stillbirth or miscarriage.
Women who become pregnant during the first 12
months of follow-up will be asked to bring their child
in for evaluation by the study doctor at their final visit
(within 3 months of pregnancy end), to document birth
date, outcomes and conduct an examination to evaluate
for any congenital abnormalities. The study team will also
ask permission to contact the labour and delivery unit
and/or paediatrician for additional details. For women
who do not return for this visit, loss to follow-up procedures will be followed including contacting the participant, home visits, and reviews of the medical record at the
facility where she sought antenatal care and/or planned
to deliver. Permission to conduct off-site visits and access
healthcare records will be obtained during the pregnancy
consenting process.

PrEP adherence
Adherence implementation will be defined as the number
of MEMS cap openings divided by the total number of
doses prescribed over the study interval in the periconception period. Adherence persistence refers to the duration of PrEP use, defined as the time (in weeks) from
PrEP initiation to either the first interval period of at least
1 week with no openings during a period of intended
overage, undetectable plasma TFV or study completion.
We will also evaluate this in the context of PrEP need
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Data analysis
Aims and outcomes
PrEP uptake
We will calculate the proportion (and 95% CI) of women
who initiate PrEP. PrEP uptake is defined as the proportion
of enrolled women who collect at least 1 month’s supply
of PrEP within the first 12 months of study participation.
We will describe and compare baseline characteristics
among those initiating PrEP versus those not initiating
PrEP and test for differences in the distribution of characteristics in the two groups using the t-test or Wilcoxon
rank sum test, as appropriate, for continuous variables
and Χ2 or Fisher exact test as appropriate for categorical
variables. Log-binomial regression will be used to model
the association between characteristics of interest (eg,
partner HIV serostatus) and PrEP initiation and to calculate unadjusted risk ratios and 95% CIs. Covariates that
are marginally associated with PrEP initiation at p<0.1 will
be considered for inclusion in multivariable models and
adjusted ORs and 95% CIs will be calculated.
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(eg, if the woman remains at risk for HIV with respect
to sexual behaviour, partner serostatus and partner viral
suppression).18
The primary adherence outcome is defined among
PrEP initiators as a protective (>40 ng/mL) plasma TFV
concentration, measured quarterly (binary outcome).
Secondary adherence outcomes are based on electronic
monitoring with MEMS caps. We will determine the mean
and median number of pills taken as well as patterns of
adherence (gaps). We will consider MEMS adherence as
a binary outcome defined as taking >80% of prescribed
doses based on biologic plausibility and prior studies.48–53
We will also explore adherence as a continuous outcome
and will determine longitudinal trends in adherence
through monthly assessments of median (IQR) adherence and adherence gaps of at least 72 hours and PrEP
use in the context of HIV-exposure.
For the prevalence of PrEP adherence (binary), we
will use a log-binomial regression model (intercept term
only) with generalised estimating equations (GEE) in
the setting of repeated measurements. We will extend
this model to include baseline and time-updated characteristics of interest to estimate unadjusted relative risks
and 95% CI. For continuous adherence outcomes using
MEMS cap data, we will describe the distribution of adherence and compare mean and median adherence levels
across the full periconception period in those exposed
versus not exposed to baseline and time-updated factors
of interest.

level motivations such as parenthood motivation, dyadic
factors such as relationship power, and community-level
factors such as functional support).
Clinical outcomes relating to PrEP safety
We will describe clinical outcomes relating to the safety
of PrEP use in pregnancy including pregnancy outcomes
(miscarriage, stillbirth and live birth) and infant outcomes
inclusive of weight, length, head circumference and
any noted congenital anomalies. Incidence rates will be
compared across women exposed/not exposed to TDF/
FTC as PrEP and also compared with population norms.
Power and sample size considerations
We will calculate the proportion of women who initiate
PrEP over a 12-month period. A target sample size of
350 women produces a 95% CI width of 9.9% when the
percent of women initiating PrEP is 70% and a 95% CI
width of 10.5% when the percent of women initiating
PrEP is 50% (eg, 70% (95% CI 65% to 75%)), providing
reasonable precision for an estimate of PrEP uptake.
Among women who initiate PrEP, we will calculate
the proportion of women adherent to at least 80% of
prescribed doses in the past month. For this and other
binary adherence outcomes, a target sample size of 245
women initiating PrEP produces a 95% CI width of 10.4%
when the percent of women who are high adherers to
PrEP is 80%. For continuous adherence outcomes, this
sample size produces a two-sided 95% CI with a distance
from the mean to the limits that is equal to 0.126 SD when
the estimated SD is 1.000.

Additional outcomes
We will also describe, as additional outcomes, pregnancy
incidence, HIV seroconversion (and compare rates
among those taking and adherent to PrEP with those
who do not take or adhere to PrEP) and all pregnancy
outcomes. The samples size will be too small to carry out
adjusted analyses, but bivariate associations will inform
factors that affect the uptake of and adherence to PrEP.
We will also evaluate the use of other safer conceptions
strategies (eg, CHCT, delay of sex without condoms until
a partner tests for HIV and is either HIV-uninfected or
HIV-positive, accessing ART and suppressed, and access
of additional services such as sperm washing.)
Longitudinal quantitative data and serial in-depth interviews with initially high-adhering and low-adhering participants as well as participants who do not initiate PrEP will
explore barriers to and promoters of PrEP uptake and
adherence while informing our conceptual framework.
Grounded theory methods will be used to analyse qualitative interview data. These methods lay out a systematic
set of inductive procedures for developing categories
of information, organising data in terms of these categories through coding, connecting the categories and
deriving from these connections an empirically grounded
theory. We will also use structural equation modelling to
examine the associations and putative causal pathways
among the hypothesised determinants of adherence as
described in the conceptual framework (eg, individual

Ethics and dissemination
This study team has considered the ethical issues in
line with ICH-GCP (The International Conference on
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use - Good Clinical
Practice) guidelines. Given normative guidance for PrEP
use in pregnancy in South Africa, the DSMB will review
safety data including adverse infant outcomes (preterm
birth (<37 weeks gestation), stillbirths, low birth weight
(<2500 g) and observed congenital anomalies). Study
clinicians will carefully monitor adverse events in women
choosing PrEP and pregnant women at all scheduled
study visits. All data on pregnancy use and TDF/FTC
exposure are reported to the Antiretrovirals in Pregnancy
Registry (http://www.apregistry.com/). Study results will
be disseminated at national and international conferences and in peer-reviewed journals. The trial findings
may also be made available to participants collectively,
should participants agree.
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Lost to follow-up data
Data from women lost to follow-up will be censored at
last contact. In addition, to adjust for potential bias due
to loss to follow-up among pregnant women, we will
conduct a sensitivity analysis using the inverse probability
of censoring weighting.54 55
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The protocol has been approved by the Human
Research Ethics Committee at the University of the
Witwatersrand (Pretoria, South Africa) and the Institutional Review Board of Partners Healthcare (Boston,
Massachusetts, USA). The protocol is registered with
the South African Health Products Regulatory Agency
(SAHPRA), MCC#20170131) and at C
 linicalTrials.
gov
(NCT03194308).
Results will be presented to local health officials
and stakeholders at meetings. Investigators will share
the results at meetings and in manuscripts. De-identified
quantitative data will be made available. Qualitative data
will not be made available due to challenges to redacting
identifiers in a potentially-stigmatised population of
HIV-exposed women planning pregnancy.56 We will aim to
follow STROBE guidelines in the presentation of results.

NIMHR01MH108412), and the Sullivan Family Foundation. Gilead Pharmaceuticals
is providing Truvada as PrEP.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use
is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

References

Funding This work is supported by funding from Massachusetts General
Hospital (Executive Committee on Research), the NIH (NIMHK23MH095655,

1. Matthews LT, Crankshaw T, Giddy J, et al. Reproductive decisionmaking and periconception practices among HIV-positive men and
women attending HIV services in Durban, South Africa. AIDS Behav
2013;17:461–70.
2. Cooper D, Moodley J, Zweigenthal V, et al. Fertility intentions and
reproductive health care needs of people living with HIV in Cape
Town, South Africa: implications for integrating reproductive health
and HIV care services. AIDS Behav 2009;13(S1):38–46.
3. Mindry D, Maman S, Chirowodza A, et al. Looking to the future:
South African men and women negotiating HIV risk and relationship
intimacy. Cult Health Sex 2011;13:589–602.
4. Myer L, Morroni C, Rebe K. Prevalence and determinants of fertility
intentions of HIV-infected women and men receiving antiretroviral
therapy in South Africa. AIDS Patient Care STDS 2007;21:278–85.
5. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV
acquisition among women throughout pregnancy and during the
postpartum period: a prospective per-coital-act analysis among
women with HIV-infected partners. J Infect Dis 2018;218:16–25.
6. Human Sciences Research Council, S.A. South African national HIV
prevalence, incidence, behaviour, and communication survey, 2017,
2018.
7. Vandormael A, Akullian Adam N, Dobra Adrian, et al. Sharp decline in
male HIV incidence in a rural South African population (2004–2015);
4–7 March 2018, Boston, Massachusetts:CROI.
8. Dovel K, Yeatman S, Watkins S, et al. Men's heightened risk of AIDSrelated death: the legacy of gendered HIV testing and treatment
strategies. AIDS 2015;29:1123–5.
9. Mambanga P, Sirwali RN, Tshitangano T. Factors contributing to
men's reluctance to seek HIV counselling and testing at Primary
Health Care facilities in Vhembe District of South Africa. Afr J Prim
Health Care Fam Med 2016;8:e1–7.
10. Mitchell S, Cockcroft A, Lamothe G, et al. Equity in HIV testing:
evidence from a cross-sectional study in ten Southern African
countries. BMC Int Health Hum Rights 2010;10:23.
11. Osler M, Hilderbrand K, Goemaere E, et al. The continuing
burden of advanced HIV disease over 10 years of increasing
antiretroviral therapy coverage in South Africa. Clin Infect Dis
2018;66:S118–S125.
12. Huerga H, Van Cutsem G, Ben Farhat J, et al. Who needs to be
targeted for HIV testing and treatment in KwaZulu-Natal? Results
from a population-based survey. J Acquir Immune Defic Syndr
2016;73:411–8.
13. World Health Organization. World Health Organization: PMTCT
strategic vision 2010-2015: preventing mother-to-child transmission
of HIV to reach the UNGASS and Millennium Development Goals.
Geneva: World Health Organization, 2010.
14. Matthews LT, Beyeza-Kashesya J, Cooke I, et al. Consensus
statement: supporting safer conception and pregnancy for
men and women living with and affected by HIV. AIDS Behav
2018;22:1713–24.
15. Matthews LT, Baeten JM, Celum C, et al. Periconception preexposure prophylaxis to prevent HIV transmission: benefits, risks,
and challenges to implementation. AIDS 2010;24:1975–82.
16. Heffron R, Pintye J, Matthews LT, et al. PrEP as peri-conception HIV
prevention for women and men. Curr HIV/AIDS Rep 2016;13:131–9.
17. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil
fumarate safety for women and their infants during pregnancy and
breastfeeding. AIDS 2017;31:213–32.
18. Haberer JE. Current concepts for PrEP adherence in the PrEP
revolution: from clinical trials to routine practice. Curr Opin HIV AIDS
2016;11:10–17.

8

Matthews LT, et al. BMJ Open 2019;9:e027227. doi:10.1136/bmjopen-2018-027227

Conclusion
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